GTCR-backed Cole-Parmer completed the acquisition of ZeptoMetrix.

GTCR-backed Cole-Parmer, a global manufacturer of proprietary products for fluidics, critical research and process equipment, completed the acquisition of ZeptoMetrix, a life sciences developer and manufacturer of quality control standards and verification panels used in molecular diagnostic testing for infectious diseases. Financial terms were not disclosed. "The addition of ZeptoMetrix is highly complementary to our existing product portfolio within the life sciences market. The acquisition underscores our dedication to serving our customers with unique, differentiated products that help accelerate their research & development programs and support their diagnostic workflows," Bernd Brust, Cole-Parmer Chief Executive Officer.